Literature DB >> 21467827

Dental patient with acromegaly: a case report.

Roopashri R Kashyap1, Gogineni S Babu, Shishir R Shetty.   

Abstract

Acromegaly is an acquired disorder related to excessive production of growth hormone after epiphyseal closure of bones. It is characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations. The prevalence is estimated at 1:140,000-250,000. Although acromegaly rarely manifests in the orofacial regions, it must be considered in patients who develop malocclusion after adolescence. Here, we present a case of acromegaly with brief review of the literature.

Entities:  

Mesh:

Year:  2011        PMID: 21467827     DOI: 10.2334/josnusd.53.133

Source DB:  PubMed          Journal:  J Oral Sci        ISSN: 1343-4934            Impact factor:   1.556


  4 in total

1.  GH-secreting pituitary macroadenoma (acromegaly) associated with progressive dental malocclusion and refractory CPAP treatment.

Authors:  Jaume Miranda-Rius; Lluís Brunet-LLobet; Eduard Lahor-Soler; David de Dios-Miranda; Josep Anton Giménez-Rubio
Journal:  Head Face Med       Date:  2017-05-10       Impact factor: 2.151

Review 2.  Oral Manifestations and Maxillo-Facial Features in the Acromegalic Patient: A Literature Review.

Authors:  Alberto De Stefani; Francesca Dassie; Alexandra Wennberg; Giorgia Preo; Alice Muneratto; Roberto Fabris; Pietro Maffei; Antonio Gracco; Giovanni Bruno
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.241

3.  The bite force and craniofacial morphology in patients with acromegaly: a pilot study.

Authors:  Duygu Karakis; Banu Aktas-Yilmaz; Arife Dogan; Ilhan Yetkin; Bulent Bek
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2014-01-01

4.  Assessment of oro-dental manifestations in a series of acromegalic patients, the AcroDent study.

Authors:  Sylvain Roumeau; Joannice Thevenon; Lemlih Ouchchane; Salwan Maqdasy; Marie Batisse-Lignier; Christian Duale; Nathalie Pham Dang; Philippe Caron; Igor Tauveron; Laurent Devoize
Journal:  Endocr Connect       Date:  2020-08       Impact factor: 3.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.